Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence

ABSTRACT:

Simple Summary

Locoregional therapies such as surgical resection, liver transplantation, and ablative techniques are preferred for early-stage HCC management. However, 70–80% of patients report HCC recurrence within 5 years of curative treatment. During the initiation and establishment of carcinogenesis, malignant cells suppress the anti-tumor immune surveillance system of the host. Therefore, modification of the immune contexture plays a crucial role in prognosis and recurrence. Following curative treatment, enhancement of effector immune cells confers effective anti-tumor immunity and good prognosis, while suppression of effector immune cells and enrichment of immunosuppressant cells promotes poor prognosis and recurrence. A combination of immunotherapeutic approaches with curat

SUBMITTER: Devan A 

PROVIDER: S-EPMC10216348 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature